Press Releases
LTS marketing campaign, a complete success – awarded!
LTS's very emotional "Animals" marketing campaign has received an extraordinary positive response. The LTS campaign was awarded 2 times.
LTS and LIVZON enter into license and collaboration agreement to develop and commercialize ASENAPINE TTS
LTS AG and Livzon Pharmaceutical Group Inc. announced today that the companies have entered into an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).
LTS appoints Bas van Buijtenen as new Chief Executive Officer
LTS Lohmann Therapie-Systeme AG is very pleased to announce the appointment of Mr. Bas van Buijtenen to the role of Chief Executive Officer effective 1 June 2020.
Completion of solar panel installation at LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is pleased to announce the completion of the installation of solar panels atop of its warehouse building of its US affiliate, LTS Lohmann Therapy Systems, Corp.
German health authorities grant LTS the manufacturer’s authorisation for capsules
Inspection successfully concluded. In September, the German health authorities extended the manufacturer’s authorisation for LTS Lohmann Therapie-Systeme AG (LTS) to include capsules.